Key result
Puerarin attenuates TGF-β1-induced hypertrophy and Smad upregulation in neonatal rat cardiomyocytes.
Why the study?
Puerarin may attenuate cardiac hypertrophy in mice, but the underlying mechanism remains unclear.
Does puerarin attenuate TGF-β1-induced hypertrophic responses and Smad protein upregulation in neonatal rat cardiomyocytes?
Does puerarin attenuate TGF-β1-induced hypertrophic responses and Smad protein upregulation in neonatal rat cardiomyocytes?
p-value: p=<0.05
Puerarin attenuates TGF-β1-induced hypertrophic responses in neonatal rat cardiomyocytes by deactivating the Smad signaling pathway.
Puerarin merits further preclinical testing in hypertrophy models; leaves open any role in human disease.
Recent studies have suggested that puerarin may attenuate cardiac hypertrophy in mice; however, the underlying mechanism remains unclear. To investigate the role of puerarin in transforming growth factor beta 1 (TGF-β1)-induced cardiac hypertrophy and the underlying mechanisms. Primary neonatal rat cardiomyocytes (NRCMs) were isolated form the heart of neonatal Wistar rats (1- to 2-day-old) and treated with different doses of puerarin (0,0.1,1or 5 g/L) in the presence of TGF-β1 (3 μg/L) to investigate the effect of puerarin on TGF-β1-induced hypertrophic changes and Smad protein alterations. RNA and protein biosynthesis in NRCMs were evaluated by synpropidium iodide staining and [3H]-leucine incorporation, respectively. Gene expression alterations were determined using quantitative real-time PCR and Western blot analysis. Compared with Smad2 knockdown, puerarin treatment (1 g/L) exhibited similar but stronger effects in abrogating TGF-β1-induced RNA and protein biosynthesis as well as fetal gene upregulation in NRCMs. In addition, puerarin treatment (1 g/L) could remarkably reverse TGF-β1-induced upregulation of Smad protein expression in NRCMs, suggesting that deactivation of the Smad signaling is possibly involved in the antihypertrophic role of puerarin. Our data suggest that puerarin may protect cardiomyoctyes against TGF-β1-induced hypertrophic responses and Smad signaling activation, providing basic dosage information and possible targets for puerarin treatment in animal models.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2020) studied Cardiac hypertrophy (in vitro model). Puerarin vs. TGF-β1 alone (3 μg/L) was evaluated on TGF-β1-induced hypertrophic responses (protein synthesis and fetal gene expression) and Smad protein expression (p=<0.05). Puerarin significantly attenuated TGF-β1-induced hypertrophic responses and Smad protein upregulation in neonatal rat cardiomyocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: